|
- Semaglutide - ALZFORUM
Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill Rybelsus TM was approved by the U S FDA in September 2019 as the first GLP-1 analog that does not need to be injected
- The Discovery and Development of Liraglutide and Semaglutide . . . - ALZFORUM
The Discovery and Development of Liraglutide and Semaglutide Front Endocrinol (Lausanne) 2019;10:155 Epub 2019 Apr 12 PubMed Recommends Please login to recommend the paper Comments No Available Comments Make a Comment To make a comment you must login or register
- Liraglutide - ALZFORUM
Diabetes, high blood sugar, and insulin resistance are all associated with dementia In Alzheimer’s disease, there is evidence for insulin resistance in the brain Thus, there has been much interest in testing liraglutide and other GLP-1 analogs, such as exendin-4, semaglutide, and lixisenatide, as potential therapeutics for AD
- Novel LC-MS MS analysis of the GLP-1 analog semaglutide with its . . .
Novel LC-MS MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats J Chromatogr B Analyt Technol Biomed Life Sci 2023 Apr 15;1221:123688 Epub 2023 Mar 22 PubMed Recommends Please login to recommend the paper Comments No Available Comments Make a Comment
- Semaglutide as a possible therapy for healthy aging: Targeting the . . .
Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging Ageing Res Rev 2024 Dec;102:102582 Epub 2024 Nov 14 PubMed Recommends Please login to recommend the paper Comments No Available Comments Make a Comment To make a comment you must login or register
- NT-0796 | ALZFORUM
In diet-induced obesity in these mice, NT-0796 caused weight loss as potently as did the GLP1 inhibitor semaglutide, and improved markers of cardiovascular risk (Thornton et al , 2024) It did not cause weight loss in non-obese mice Findings
- Semaglutide Attenuates Anxious and Depressive-Like Behaviors and . . .
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis J Neuroimmune Pharmacol 2024 Jul 23;19(1):36
- Protocol for a double-blind placebo-controlled randomised controlled . . .
Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults BMJ Open 2024 Jun 21;14(6):e081401 PubMed Recommends Please login to recommend the paper Comments No Available Comments Make a Comment
|
|
|